Broadstreet is pleased to have contributed to seven studies being presented at ISPOR on subjects ranging from patient preferences for chronic obstructive pulmonary disease (COPD) maintenance treatment delivery devices to a qualitative analysis of social media data to understand Medication-taking behaviour in attention-deficit hyperactivity disorder (ADHD).

This latter study is some of our own research exploring the potential for social media forums to act as source of real-world data on how and why people take their medications in the way they do. Our study sought to explore how individuals with ADHD describe and discuss their intentional medication-taking behaviours, including the personal, social and structural contexts that drive decision-making. To our knowledge these types of data had not been used previously to explore these themes in ADHD. Our findings highlight the variability in ADHD medication-taking
behaviour, and the reasons underlying it. We hope the insights from the study Ideally will help clinicians
better understand their patients’ motivations, and researchers understand how people take ADHD medications in real-world settings.

We invite you to check out all our posters:

In Session 2 on Tuesday, May 18th:

MSR63 – Target trial emulation (TTE) informed by clinical trial data: adjuvant nivolumab vs observation in patients with resectable non-small cell lung cancer (RNSCLC) after neoadjuvant nivolumab plus chemotherapy and surgery

Greta Lozano-Ortega, MSc¹, Basia Rogula, MSc¹, Stefano Lucherini, MSc², Sumeena Bhatia, PhD³, Samantha Wilusz, PharmD³, Mariam Besada, MPH¹, Lavanya Huria, MSc¹, Eleanor Murray, ScD⁴.
¹Broadstreet HEOR, Vancouver, BC, Canada, ²Bristol Myers Squibb, Uxbridge, United Kingdom, ³Bristol Myers Squibb, Princeton, NJ, USA, ⁴Independent Scholar, Boston, MA, USA.

In Session 3 on Tuesday, May 18^th:

EE211 – Budget impact analysis of sonpiretigene isteparvovec for retinitis pigmentosa with severe vision loss

Karissa M. Johnston, BSc, MSc, PhD¹, Anish Patel, PharmD², Jessica S. Dunne, MSc¹, Samar Mohanty, PhD², Ramesh V. Arjunji, PhD².
¹Broadstreet HEOR, Vancouver, BC, Canada, 2Nanoscope Therapeutics, Inc., Dallas, TX, USA.

EE210 – Cost effectiveness analysis of sonpiretigene isteparvovec for retinitis pigmentosa with severe vision loss

Andrew Davies, MSc¹, Anish Patel, PharmD², Jessica S. Dunne, MSc³, Karissa M. Johnston, BSc, MSc, PhD³, Samar Mohanty, PhD², Ramesh V. Arjunji, PhD².
¹Stockbridge Economic Appraisal Ltd, Edinburgh, United Kingdom, ²Nanoscope Therapeutics, Inc., Dallas, TX, USA, ³Broadstreet HEOR, Vancouver, BC, Canada.

In Session 4 on Wednesday, May 19^th:

EE349 – Cross-validation of an early cost-effectiveness model for Spectris™ therapy using the Alzheimer’s disease open-source IPECAD model framework

Chantal W. van Gils, MSc, PhD, MD¹, Joseph D. Massey, MEng², Kai-Erh Kao, MSc³, Karissa M. Johnston, BSc, MSc, PhD³, Kathleen A. Troeger, MPH⁴.
¹VP Evidence and Value, SSI Strategy, Rotterdam, Netherlands, ²SSI Strategy, London, United Kingdom, ³Broadstreet HEOR, Vancouver, BC, Canada, ⁴Cognito Therapeutics, Cambridge, MA, USA.

CO150 – Safety of sepiapterin and pegvaliase for the treatment of phenylketonuria (PKU): a simulated treatment comparison (STC)

Fiona O’Sullivan, PhD¹, Juan Pablo Diaz-Martinez, PhD (c)¹, Ida Schwartz, Sr., MD², Karissa M. Johnston, BSc, MSc, PhD¹, Ioannis Tomazos, MBA, PhD³;
¹Broadstreet HEOR, Vancouver, BC, Canada, ²Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Department of Genetics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³PTC Therapeutics, Executive Director, Head of GHEOR, Warren, NJ, USA

PT35 – Evaluating patient preferences for COPD maintenance treatment delivery devices: a discrete choice experiment

Suzanne McMullen, MHA¹, Michael Hess, MPH², Alexis T. Mickle, MSc¹, Grace Leung, MPH³, Joseph Cook, JD, PhD⁴, Misty Green, MSc², Mark Luttmann, BSc², Karissa M. Johnston, PhD¹, Sarah Walker, MSc.¹, Bruce Miller, PhD²;
¹Broadstreet HEOR, Vancouver, BC, Canada, ²COPD Foundation, Miami, FL, USA, ³Theravance Biopharma US, San Francisco, CA, USA, ⁴Viatris Inc, Mamaroneck, NY, USA